Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity

UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity

FinvizFinviz2026/02/14 06:30
By:Finviz

UniQure (NASDAQ:QURE) is one of the most promising low-cost stocks to buy now. On February 6, UniQure reported positive updated data from its Phase I/IIa trial of AMT-191, which is a gene therapy for Fabry disease. All 11 patients across three different dose levels showed increased enzyme activity, with the longest-treated patient maintaining these high levels for over a year. Notably, the enzyme levels were significantly above normal ranges, showing a clear relationship between the dose received and the amount of enzyme produced.

The treatment allowed 6 out of the 11 patients to stop their regular enzyme replacement therapy/ERT after meeting specific clinical criteria. Even after stopping ERT, patients maintained stable levels of lyso-Gb3, the toxic substance that typically builds up in Fabry disease. This suggests that the one-time gene therapy could potentially replace the need for lifelong, bi-weekly infusions for some patients.

While the therapy shows promise, UniQure has paused new dosing in the mid- and high-dose groups to evaluate some safety findings. Two patients in the middle dose group experienced high liver enzyme levels that were classified as dose-limiting toxicities, though both responded to steroid treatment. Other previously reported serious events in the high-dose group included chest pain and a stroke, though some were determined to be unrelated to the study drug.

UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity image 0

UniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases in the US.

READ NEXT:
 and
.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI demand surges, but the financing "credit gate" is tightening! Under the heavy pressure of the 5% U.S. Treasury yield, compute power losers are gradually emerging

As U.S. Treasury yields rise to their highest levels since 2007, the overall financing cost for AI infrastructure construction is set to become significantly higher. JPMorgan predicts that by 2030, AI-related debt will reach $4.1 trillion.

智通财经•2026/09/28 01:46

From Saving Credit Suisse to Considering Cross-border Mergers: UBS (UBS.US) Faces a "Capital Siege", Is the Next Step Joining Forces with Wall Street?

As Switzerland's largest bank faces pressure from stricter capital requirements, several major international banks have approached UBS regarding potential mergers or other collaborations.

智通财经•2026/09/28 01:46
From Saving Credit Suisse to Considering Cross-border Mergers: UBS (UBS.US) Faces a "Capital Siege", Is the Next Step Joining Forces with Wall Street?